ArticleClinical epigenetics2026
Epigenetic ageing during the COVID-19 pandemic: global age acceleration, independent of SARS-CoV-2 infection.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionThe COVID-19 pandemic had profound effects for both infected and uninfected individuals. We aimed to identify acute and chronic epigenetic alterations from SARS-CoV-2 infection and/or lockdown measures.
methodsBoth infected and uninfected participants from the TwinsUK cohort (n = 139) provided longitudinal whole-blood samples (Spring 2020, Spring 2021). Cross-sectional and longitudinal DNA methylome [DNAm] changes, including epigenetic ageing clocks, were assessed, and EWAS (Epigenome-Wide Association Studies) were performed. Changes in epigenetic ageing clocks were compared with longitudinal samples from an independent pre-pandemic cohort (n = 35, Nurses' Health Study II cohort), assessed similarly.
resultsIrrespective of SARS-CoV-2 infection, all individuals exhibited accelerated ageing from 2020 to 2021 (GrimAge clock age acceleration: p-value = 0.002, β = 0.99). In contrast, epigenetic data from paired samples from a separate pre-pandemic cohort, over a similar time period and assessed similarly, did not exhibit GrimAge acceleration. Epigenetic ageing did not differ between infected and uninfected individuals, or between recent and distant SARS-CoV-2 infection. Lastly, EWAS identified several putative changes in DNAm associated with recent, and distant, SARS-CoV-2 infection.
conclusionsOur longitudinal results suggest that the pandemic accelerated epigenetic ageing rates, irrespective of recent or distant SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.